Aktis Oncology priced an upsized IPO that raised $318 million, selling shares at $18 apiece and opening trading with a sharp pop. The radiopharmaceutical developer’s debut signals renewed investor appetite for growth-stage biopharma, led by a miniprotein radioconjugate platform and a discovery tie-up with Eli Lilly. Separately, Eikon Therapeutics filed for a U.S. IPO, positioning its high‑resolution cellular imaging platform as an early-market test of whether 2026 can sustain a biotech public offering window. The filings and debuts may influence deal timing and valuations for other private biotechs planning exits this year.